Molecular mode of action and role of tp53 in the sensitivity to the novel epothilone sagopilone (zk-epo) in a549 non-small cell lung cancer cells

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Winsel, Sebastian ^a,b,c   Sommer, Anette ^a   Eschenbrenner, Julia ^a,d   Mittelstaedt, Kevin ^a,e   Klar, Ulrich ^a   Hammer, Stefanie ^a   Hoffmann, Jens ^a,f  

^a Global Drug Discovery   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^d TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; SAGOPILONE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPOTHILONE DERIVATIVE; PROTEIN P53; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BUBR1 GENE; CANCER CELL; CANCER RESISTANCE; CDKN1A GENE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN B1 GENE; CYTOSKELETON; DNA DAMAGE; DRUG MECHANISM; GADD45A GENE; GENE; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MDM2 GENE; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; TP53 GENE; UPREGULATION; CELL PROLIFERATION; DNA MICROARRAY; GENETICS; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PHENOTYPE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOTHIAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETON; DNA DAMAGE; EPOTHILONES; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 79955770594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019273     Document Type: Article

References (55)

1. Global Cancer Facts & Figures 2007, http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf. American Cancer Society. Accessed on November 30, 2009.
2. General Information about Non-Small Cell Lung Cancer, http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/HealthProfessional. National Cancer Institute. Accessed on November 11, 2009.
3. Horner MJ RL, Krapcho M, Neyman N, Aminou R, Howlader N, et al.eds. (2009) SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site.
4. Rigas JR, (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 (Suppl 2): 16-23.
5. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, et al. (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr pp. 55-61.
6. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, et al. (2006) Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 45: 7942-7948.
7. Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, et al. (2010) Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res 16: 1452-1465.
8. Altaha R, Liang X, Yu JJ, Reed E, (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970.
9. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 4: e4576.
10. Gazdar AF, (2009) Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361: 1018-1020.
11. Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, et al. (2008) Molecular mechanisms of patupilone resistance. Cancer Res 68: 10197-10204.
12. Vousden KH, Lane DP, (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
13. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, et al. (1999) Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18: 1007-1014.
14. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300.
15. Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM, (1998) Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047-1054.
16. Hawkins DS, Demers GW, Galloway DA, (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898.
17. Vikhanskaya F, Vignati S, Beccaglia P, Ottoboni C, Russo P, et al. (1998) Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 241: 96-101.
18. Seve P, Dumontet C, (2005) Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 5: 73-88.
19. Coate LE, John T, Tsao MS, Shepherd FA, (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10: 1001-1010.
20. Lichtner RB, Rotgeri A, Bunte T, Buchmann B, Hoffmann J, et al. (2001) Subcellular distribution of epothilones in human tumor cells. Proc Natl Acad Sci U S A 98: 11743-11748.
21. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, et al. (2002) Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 265: 39-47.
22. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
23. Sullivan M, Morgan DO, (2007) Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8: 894-903.
24. Nigg EA, (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32.
25. Musacchio A, Salmon ED, (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8: 379-393.
26. Popanda O, Thielmann HW, (1992) The function of DNA polymerases in DNA repair synthesis of ultraviolet-irradiated human fibroblasts. Biochim Biophys Acta 1129: 155-160.
27. Jin S, Weaver DT, (1997) Double-strand break repair by Ku70 requires heterodimerization with Ku80 and DNA binding functions. Embo J 16: 6874-6885.
28. Riley KJ, Maher LJ 3rd, (2007) p53 RNA interactions: new clues in an old mystery. RNA 13: 1825-1833.
29. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, et al. (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301-5308.
30. Torres K, Horwitz SB, (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626.
31. Chen JG, Yang CP, Cammer M, Horwitz SB, (2003) Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63: 7891-7899.
32. Bergstralh DT, Taxman DJ, Chou TC, Danishefsky SJ, Ting JP, (2004) A comparison of signaling activities induced by Taxol and desoxyepothilone B. J Chemother 16: 563-576.
33. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
34. Blagosklonny MV, (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6: 70-74.
35. Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E, et al. (2008) Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 27: 4402-4410.
36. Aylon Y, Oren M, (2007) Living with p53, dying of p53. Cell 130: 597-600.
37. Das S, Boswell SA, Aaronson SA, Lee SW, (2008) P53 promoter selection: choosing between life and death. Cell Cycle 7: 154-157.
38. Blagosklonny MV, (2006) Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. Cell Cycle 5: 971-975.
39. Sherr CJ, Roberts JM, (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
40. Janicke RU, Sohn D, Essmann F, Schulze-Osthoff K, (2007) The multiple battles fought by anti-apoptotic p21. Cell Cycle 6: 407-413.
41. Heliez C, Baricault L, Barboule N, Valette A, (2003) Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22: 3260-3268.
42. Suzuki A, Tsutomi Y, Miura M, Akahane K, (1999) Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18: 1239-1244.
43. Xu SQ, El-Deiry WS, (2000) p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269: 179-190.
44. Blagosklonny MV, Fojo T, (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156.
45. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, et al. (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738-747.
46. Zuco V, Zunino F, (2008) Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia 10: 587-596.
47. Ling YH, Zou Y, Perez-Soler R, (2000) Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res 20: 693-702.
48. Ioffe ML, White E, Nelson DA, Dvorzhinski D, DiPaola RS, (2004) Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate 61: 243-247.
49. Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, et al. (2004) Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 279: 30195-30201.
50. Hoagland MS, Hoagland EM, Swanson HI, (2005) The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther 314: 603-610.
51. Kaji A, Zhang Y, Nomura M, Bode AM, Ma WY, et al. (2003) Pifithrin-alpha promotes p53-mediated apoptosis in JB6 cells. Mol Carcinog 37: 138-148.
52. Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, et al. (2009) Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ 16: 869-878.
53. Fischer J, von Pawel J, Schmittel A, (2008) Phase II trials of the novel epothilone sagopilone (ZK-EPO), a novel epothilone, as second-line therapy in patients with stage IIIB-IV non-small-cell lung cancer. 33 2008:30 Stockholm (Schweden) ESMO.
54. Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, et al. (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21: 633-639.
55. Gudkov AV, Komarova EA, (2005) Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331: 726-736.